Literature DB >> 3827259

[Comparison between the succinate dehydrogenase inhibition test and ATP assay for in vitro chemosensitivity testing].

Y Maehara, K Miyamoto, H Anai, H Kusumoto, K Fukuchi, H Masuda, K Sugimachi.   

Abstract

The predicted level of cell viability was compared between the succinate dehydrogenase inhibition (SDI) test and the adenosine triphosphate (ATP) assay, both of which are used for in vitro human tumor chemosensitivity testing. After HeLa cells had been exposed to various concentrations of 5-FU for 1, 2, 3 or 4 days, the decrease occurring in viable cell number correlated with that of succinate dehydrogenase (EC 1.3.99.1) activity and that of the intracellular ATP level of the viable cells. In dead cells, the ATP level was extensively decreased, but the succinate dehydrogenase activity remained at a level of 11% of that of 5-FU-untreated viable cells, even on day 4. The cell viability correlated well with the intracellular ATP level, as compared with the succinate dehydrogenase activity. The activity remaining in dead cells must thus be taken into consideration for the prediction of chemosensitivity in the SDI test, but not in the ATP assay.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3827259

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  3 in total

1.  Human glioma demonstrates cell line specific results with ATP-based chemiluminescent cellular proliferation assays.

Authors:  Michael E Sughrue; Martin J Rutkowski; Ari J Kane; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-09-09       Impact factor: 1.961

2.  Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures.

Authors:  O R Koechli; G N Schaer; V Schenk; U Haller; H Walt
Journal:  Arch Gynecol Obstet       Date:  1995       Impact factor: 2.344

3.  Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-cell viability assay.

Authors:  O R Koechli; B U Sevin; J P Perras; T C Chou; R Angioli; A Steren; M Untch; H E Averette
Journal:  Breast Cancer Res Treat       Date:  1993-10       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.